Lipid Research Group, School of Medical Sciences, The University of New South Wales, Australia.
Lipid Research Group, School of Medical Sciences, The University of New South Wales, Australia.
Atherosclerosis. 2018 Nov;278:143-146. doi: 10.1016/j.atherosclerosis.2018.09.033. Epub 2018 Sep 26.
Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). While treatment with a statin reduces the risk of having an ASCVD event in all people, including those with type-2 diabetes, statin treatment also increases the likelihood of new onset diabetes when given to those with risk factors for developing diabetes. Treatment with the cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, reduces the risk of having a coronary event over and above that achieved with a statin. However, unlike statins, anacetrapib decreases the risk of developing diabetes. If the reduced risk of new-onset diabetes is confirmed in another CETP inhibitor outcome trial, there will be a case for considering the use of the combination of a statin plus a CETP inhibitor in high ASCVD-risk people who are also at increased risk of developing diabetes.
2 型糖尿病是动脉粥样硬化性心血管疾病（ASCVD）发展的一个因果风险因素。虽然他汀类药物治疗可降低所有人群（包括 2 型糖尿病患者）发生 ASCVD 事件的风险，但在有发生糖尿病风险的人群中，他汀类药物治疗也会增加新发糖尿病的可能性。胆固醇酯转移蛋白（CETP）抑制剂依折麦布的治疗可降低发生冠状动脉事件的风险，超过他汀类药物的效果。然而，与他汀类药物不同的是，依折麦布可降低发生糖尿病的风险。如果在另一个 CETP 抑制剂的结果试验中证实了新发糖尿病风险的降低，那么对于那些 ASCVD 风险高且发生糖尿病风险增加的人群，就有理由考虑使用他汀类药物联合 CETP 抑制剂。
